<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/E4757A6E-7326-472B-9979-B47D77A65446"><gtr:id>E4757A6E-7326-472B-9979-B47D77A65446</gtr:id><gtr:name>Aberystwyth University</gtr:name><gtr:department>IBERS</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>King Street</gtr:line2><gtr:line3>Ceredigion</gtr:line3><gtr:line4>Aberystwyth</gtr:line4><gtr:line5>Dyfed</gtr:line5><gtr:postCode>SY23 2AX</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E4757A6E-7326-472B-9979-B47D77A65446"><gtr:id>E4757A6E-7326-472B-9979-B47D77A65446</gtr:id><gtr:name>Aberystwyth University</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>King Street</gtr:line2><gtr:line3>Ceredigion</gtr:line3><gtr:line4>Aberystwyth</gtr:line4><gtr:line5>Dyfed</gtr:line5><gtr:postCode>SY23 2AX</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/5362799D-305E-40FD-97F1-D1140C3B0396"><gtr:id>5362799D-305E-40FD-97F1-D1140C3B0396</gtr:id><gtr:firstName>Karl</gtr:firstName><gtr:surname>Hoffmann</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FI532937%2F1"><gtr:id>6ECDBBC9-855E-44BC-B5E9-C6EC101F03D7</gtr:id><gtr:title>Validation of a commercial Helminth Viability Screening Assay for drug discovery against parasites of veterinary importance</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/I532937/1</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2012-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2011-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>114249</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>The main achievement associated with this research project was adapting an existing assay to high-throughput determination of Fasciola hepatica (a parasitic fluke) larvae viability. As this parasite causes an estimated US$3.2 billion loss in the livestock industry/annum and control is restricted to limited drug classes, the animal health industry has an active interest in methodological developments in identifying novel flukicides. Towards this end, our sharing of this output with Pharma has led to current licensing negotiations.</gtr:description><gtr:exploitationPathways>We are currently in commercial discussions with the animal health sector to identify how best to proceed with our developed technology. Licensing and fee for service negotiations are currently ongoing between Pharma and our commercialisation department. We are also applying the technology developed during this research project to a EU/FP7 grant (submitted Feb 6, 2012) focused on identifying novel anthelmintic compounds. Together, both of these exploitation routes are expected to improve animal and human health.</gtr:exploitationPathways><gtr:id>637CB539-1808-4BD8-B3F8-D6E48A7EB446</gtr:id><gtr:outcomeId>r-9975066333.985949774cf4ca</gtr:outcomeId><gtr:sectors><gtr:sector>Agriculture, Food and Drink,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors><gtr:url>http://gtr.rcuk.ac.uk/project/6ECDBBC9-855E-44BC-B5E9-C6EC101F03D7</gtr:url></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>27D3F8C4-BEB5-4743-B99C-5F962223F71E</gtr:id><gtr:title>The diterpenoid 7-keto-sempervirol, derived from Lycium chinense, displays anthelmintic activity against both Schistosoma mansoni and Fasciola hepatica.</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c78fa5be9ea72233e395b97d5bf51ef"><gtr:id>7c78fa5be9ea72233e395b97d5bf51ef</gtr:id><gtr:otherNames>Edwards J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn><gtr:outcomeId>562a0df49780f1.41816907</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C27F8CA-C1E3-4982-BD3B-87147794AF86</gtr:id><gtr:title>Drug-induced exposure of Schistosoma mansoni antigens SmCD59a and SmKK7.</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2905bc3f1bf122071df3f97e28f881aa"><gtr:id>2905bc3f1bf122071df3f97e28f881aa</gtr:id><gtr:otherNames>Reimers N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn><gtr:outcomeId>562a0e2ed63068.04643530</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A9D43441-438A-4D64-B447-98DDA22A25E8</gtr:id><gtr:title>Crystal structure of Schistosoma mansoni arginase, a potential drug target for the treatment of schistosomiasis.</gtr:title><gtr:parentPublicationTitle>Biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77f5dd9fc9191277f17ef60190df23a8"><gtr:id>77f5dd9fc9191277f17ef60190df23a8</gtr:id><gtr:otherNames>Hai Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-2960</gtr:issn><gtr:outcomeId>541963e1716c15.84769535</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/I532937/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>